Literature DB >> 10962580

Identification of genomic DNA sequences bound by mutant p53 protein (Gly245-->Ser) in vivo.

H Koga1, W Deppert.   

Abstract

Mutant p53 proteins were shown to exert complex DNA-interactions in vitro, like binding to MAR-DNA, but so far it is unknown whether such interactions also occur in vivo. Therefore we analysed the binding of mutant (mut) p53 (Gly245-->Ser) in Onda 11 glioma cells to cellular DNA in vivo, using p53-specific chromatin immunoprecipitation (CHIP) after in vivo cross-linking of mut p53 to genomic DNA with cisplatin. We identified genomic DNA fragments to which mut p53 (Gly245-->Ser) could be cross-linked in vivo. Purified recombinant mut p53 (Gly245-->Ser) was able to bind specifically to such elements in PCR-EMSA in vitro, supporting the idea that this mut p53 protein interacts with genomic DNA in vivo. The genomic DNA fragments identified are vastly different in sequence, but display as a common feature a high likelihood to adopt a non B-DNA conformation. Therefore we propose that structural determinants within these DNA elements are important for their interaction with mut p53 (Gly245-->Ser) in vivo. Oncogene (2000) 19, 4178 - 4183

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962580     DOI: 10.1038/sj.onc.1203745

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Maxizyme-mediated specific inhibition on mutant-type p53 in vitro.

Authors:  Xin-Juan Kong; Yu-Hu Song; Ju-Sheng Lin; Huan-Jun Huang; Nan-Xia Wang; Nan-Zhi Liu; Bin Li; You-Xin Jin
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

Review 2.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

Review 3.  When mutants gain new powers: news from the mutant p53 field.

Authors:  Ran Brosh; Varda Rotter
Journal:  Nat Rev Cancer       Date:  2009-08-20       Impact factor: 60.716

4.  Three assays show differences in binding of wild-type and mutant p53 to unique gene sequences.

Authors:  Uma Chandrachud; Susannah Gal
Journal:  Technol Cancer Res Treat       Date:  2009-12

Review 5.  Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme.

Authors:  Bryant England; Tiangui Huang; Michael Karsy
Journal:  Tumour Biol       Date:  2013-06-05

6.  Mutant p53 proteins bind DNA in a DNA structure-selective mode.

Authors:  Thomas Göhler; Stefan Jäger; Gabriele Warnecke; Hideyo Yasuda; Ella Kim; Wolfgang Deppert
Journal:  Nucleic Acids Res       Date:  2005-02-18       Impact factor: 16.971

Review 7.  Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers.

Authors:  Maria Ferraiuolo; Lorena Verduci; Giovanni Blandino; Sabrina Strano
Journal:  Int J Mol Sci       Date:  2017-05-03       Impact factor: 5.923

8.  Modulation of gene expression in U251 glioblastoma cells by binding of mutant p53 R273H to intronic and intergenic sequences.

Authors:  Marie Brázdová; Timo Quante; Lars Tögel; Korden Walter; Christine Loscher; Vlastimil Tichý; Lenka Cincárová; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Nucleic Acids Res       Date:  2009-01-12       Impact factor: 16.971

9.  Preferential binding of hot spot mutant p53 proteins to supercoiled DNA in vitro and in cells.

Authors:  Marie Brázdová; Lucie Navrátilová; Vlastimil Tichý; Kateřina Němcová; Matej Lexa; Roman Hrstka; Petr Pečinka; Matej Adámik; Borivoj Vojtesek; Emil Paleček; Wolfgang Deppert; Miroslav Fojta
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

10.  NAMPT Inhibitor and P73 Activator Represses P53 R175H Mutated HNSCC Cell Proliferation in a Synergistic Manner.

Authors:  Bi-He Cai; Zhi-Yu Bai; Ching-Feng Lien; Si-Jie Yu; Rui-Yu Lu; Ming-Han Wu; Wei-Chen Wu; Chia-Chi Chen; Yi-Chiang Hsu
Journal:  Biomolecules       Date:  2022-03-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.